These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 6986409

  • 1. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
    Samojlik E, Veldhuis JD, Wells SA, Santen RJ.
    J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
    [Abstract] [Full Text] [Related]

  • 2. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
    Samojlik E, Santen RJ, Kirschner MA, Ertel NH.
    Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
    [Abstract] [Full Text] [Related]

  • 3. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
    Santen RJ, Worgul TJ, Samojlik E, Boucher AE, Lipton A, Harvey H.
    Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
    [Abstract] [Full Text] [Related]

  • 4. How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
    Worgul TJ, Santen RJ, Samojlik E, Wells SA.
    J Clin Endocrinol Metab; 1982 Jan; 54(1):22-6. PubMed ID: 6459336
    [Abstract] [Full Text] [Related]

  • 5. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
    Samojlik E, Santen RJ.
    J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517
    [Abstract] [Full Text] [Related]

  • 6. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
    Simon J, Klaiber E, Wiita B, Bowen A, Yang HM.
    Menopause; 1999 Oct; 6(2):138-46. PubMed ID: 10374221
    [Abstract] [Full Text] [Related]

  • 7. High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy.
    Morris KT, Toth-Fejel S, Schmidt J, Fletcher WS, Pommier RF.
    Surgery; 2001 Dec; 130(6):947-53. PubMed ID: 11742322
    [Abstract] [Full Text] [Related]

  • 8. Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison.
    Castelo-Branco C, Martínez de Osaba MJ, Fortuny A, Iglesias X, González-Merlo J.
    J Reprod Med; 1995 Aug; 40(8):556-60. PubMed ID: 7473451
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.
    Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA.
    N Engl J Med; 1981 Sep 03; 305(10):545-51. PubMed ID: 7019703
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cancer of the breast. Endocrine and hormonal therapy.
    Kardinal CG, Donegan WL.
    Major Probl Clin Surg; 1979 Sep 03; 5():361-404. PubMed ID: 379452
    [Abstract] [Full Text] [Related]

  • 13. [The use of aminoglutethimide in the treatment of metastatic breast cancer].
    Bellora MG, Ciancio A, Ferrero A, Bergamino T, Zola P, Sismondi P.
    Minerva Ginecol; 1991 Dec 03; 43(12):589-93. PubMed ID: 1819778
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ovarian and adrenal contributions to peripheral steroid levels in postmenopausal women.
    Maroulis GB, Abraham GE.
    Obstet Gynecol; 1976 Aug 03; 48(2):150-4. PubMed ID: 133306
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
    Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ.
    Clin Genitourin Cancer; 2009 Oct 03; 7(3):E71-6. PubMed ID: 19815485
    [Abstract] [Full Text] [Related]

  • 18. Influence of conjugated oestrogens on circulating oestradiol, oestrone, LH, FSH and prolactin levels in postmenopausal women.
    Luisi M, Franchi F, Argenio GF, Barletta D, Romano MR, Bernini GP, Gasperi M, Sgrilli R.
    Int J Tissue React; 1981 Jun 03; 3(2):77-81. PubMed ID: 6799393
    [Abstract] [Full Text] [Related]

  • 19. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE, Anania C, Malinak R.
    J Reprod Med; 1996 Sep 03; 41(9):645-52. PubMed ID: 8887188
    [Abstract] [Full Text] [Related]

  • 20. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT, Le H, McFann KK, Blackman MR.
    Am J Physiol Endocrinol Metab; 2005 Mar 03; 288(3):E573-84. PubMed ID: 15536203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.